Personal tools

Coexpression cluster:C3873: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
(Created page with "{{Coexpression_clusters |full_id=C3873_neuroblastoma_nonsmall_teratocarcinoma_acute_neuroectodermal_medulloblastoma_small |id=C3873 }}")
 
No edit summary
Line 2: Line 2:
|full_id=C3873_neuroblastoma_nonsmall_teratocarcinoma_acute_neuroectodermal_medulloblastoma_small
|full_id=C3873_neuroblastoma_nonsmall_teratocarcinoma_acute_neuroectodermal_medulloblastoma_small
|id=C3873
|id=C3873
|ontology_enrichment_celltype=CL:0000012!4.64e-27!682;CL:0000548!3.32e-26!679;CL:0000004!3.32e-26!679;CL:0000255!3.32e-26!679;CL:0000066!2.88e-17!254;CL:0002321!3.71e-15!248;CL:0000220!1.79e-14!246;CL:0000003!5.78e-14!722;CL:0000144!3.26e-11!625;CL:0000055!5.22e-11!180;CL:0002139!2.79e-09!24;CL:0000071!2.32e-08!18;CL:0002546!2.32e-08!18;CL:0000076!3.50e-08!62;CL:0000222!3.57e-08!119;CL:0002319!2.06e-07!25;CL:0000063!2.18e-07!578
|ontology_enrichment_disease=DOID:162!2.88e-43!235;DOID:14566!3.27e-43!239;DOID:0050686!9.62e-22!137;DOID:0050687!2.89e-21!143;DOID:305!1.61e-17!106;DOID:2531!2.19e-14!51;DOID:0060083!2.19e-14!51;DOID:1240!9.76e-12!39;DOID:8692!5.40e-09!31;DOID:3095!8.19e-07!22;DOID:2994!8.19e-07!22
|ontology_enrichment_uberon=UBERON:0000487!5.04e-09!22;UBERON:0001986!2.32e-08!18;UBERON:0004638!2.32e-08!18;UBERON:0004852!2.32e-08!18;UBERON:0006914!3.56e-08!25;UBERON:0000055!4.27e-07!69;UBERON:0000490!5.42e-07!138;UBERON:0001737!5.73e-07!9;UBERON:0000072!8.58e-07!46
}}
}}

Revision as of 14:41, 21 May 2012


Full id: C3873_neuroblastoma_nonsmall_teratocarcinoma_acute_neuroectodermal_medulloblastoma_small



Phase1 CAGE Peaks

Hg19::chr1:153643418..153643429,-p2@ILF2
Hg19::chr1:153643442..153643475,-p1@ILF2
Hg19::chr1:156308018..156308101,-p1@CCT3


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


No GOStat results

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>


Uber Anatomy
Ontology termp-valuen
simple squamous epithelium5.04e-0922
endothelium2.32e-0818
blood vessel endothelium2.32e-0818
cardiovascular system endothelium2.32e-0818
squamous epithelium3.56e-0825
vessel4.27e-0769
unilaminar epithelium5.42e-07138
larynx5.73e-079
segment of respiratory tract8.58e-0746
Disease
Ontology termp-valuen
cancer2.88e-43235
disease of cellular proliferation3.27e-43239
organ system cancer9.62e-22137
cell type cancer2.89e-21143
carcinoma1.61e-17106
hematologic cancer2.19e-1451
immune system cancer2.19e-1451
leukemia9.76e-1239
myeloid leukemia5.40e-0931
germ cell and embryonal cancer8.19e-0722
germ cell cancer8.19e-0722


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data


This analysis result is provided for C0 - C305 clusters.